Ainos signs global exclusive license for Veldon technology
Ainos has entered into a global exclusive license agreement with BioPhoenix Co., Ltd. to commercialize the Veldon technology platform for indications including Sjögren's Disease and Thrombocytopenia.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed